WASHINGTON — The pharmaceutical industry is weighing two drug pricing policies that it could offer as a trade to President Trump, in exchange for his dropping a different proposal that drug makers detest, according to three drug industry lobbyists and a summary of the potential changes obtained by STAT.
Trump told drug makers last month they had until Monday to come up with a way to significantly lower drug prices, or he would implement, via executive order, a “Most Favored Nations” policy, which would require drug makers sell injectable drugs for the lowest price they offer similar countries. Despite the deadline passing, the White House has not yet moved to implement the policy.
About the Author Reprints
